Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [<sup>68</sup>Ga]Ga-LNTH-1363S on Image Quality.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.

Acta neuropathologica·2026

Same author

Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma.

Cancer medicine·2026

Same author

Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations-a critical evaluation on real world data.

The oncologist·2025

Same author

Correction: Identification of AAV variants with improved transduction of human vascular endothelial cells by screening AAV capsid libraries in non-human primates.

Gene therapy·2025

Same author

Determinants of quality of life among lung cancer patients: insights from a cross-sectional study.

European archives of psychiatry and clinical neuroscience·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Lapatinib.

Tanja Schneider-Merck¹, Martin Trepel

¹Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. t.schneider-merck@uke.de

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer

|January 15, 2010

Summary

Lapatinib, a dual tyrosine kinase inhibitor, shows antitumor activity in advanced HER2-positive breast cancer. It offers an alternative to trastuzumab with fewer cardiac side effects, particularly when combined with capecitabine.

Area of Science:

Oncology
Pharmacology

Background:

The human epidermal growth factor receptor (HER) family is crucial in cancer biology.
HER2 overexpression in breast cancer correlates with poor prognosis, necessitating targeted therapies.
Trastuzumab is an effective HER2-targeted therapy, but limitations exist.

Purpose of the Study:

To evaluate lapatinib, a novel dual tyrosine kinase inhibitor, for HER2-positive breast cancer.
To assess lapatinib's efficacy and safety profile, especially its cardiac impact compared to trastuzumab.
To explore lapatinib's role in advanced or refractory HER2-positive breast cancer.

Main Methods:

Lapatinib inhibits HER1 and HER2 tyrosine kinase activity by blocking ATP binding.
Clinical trials assessed lapatinib's antitumor activity, tolerability, and adverse effects.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 17, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Combination therapy with capecitabine was investigated in patients with progressive disease.

Main Results:

Lapatinib demonstrated substantial antitumor activity in advanced HER2-positive breast cancer.
The drug is well-tolerated with minimal cardiac adverse effects, unlike trastuzumab.
Combination therapy with capecitabine showed efficacy after standard treatments failed.

Conclusions:

Lapatinib is a promising therapeutic option for advanced HER2-positive breast cancer.
Its favorable safety profile, particularly regarding cardiac function, is advantageous.
Further research will investigate lapatinib in adjuvant settings, other combinations, and different cancer types.